• Twitter
  • Jobs
ProCURE oncology
  • HOME
  • ABOUT US
  • RESEARCH GROUP
    • Molleví’s Lab
    • Antolin’s Lab
    • Alemany’s & Piulats’s lab
    • Martínez-Balibrea’s Lab
    • Aytes’s Lab
    • Belver’s Lab
    • Pujana’s Lab
    • Menendez’s Lab
    • Sureda’s & Farre’s Lab
    • Casanovas’s Lab
    • Viñals’s lab
  • INNOVATION
  • NEWS
  • CONTACT
  • Menu Menu

The interplay between molecular architecture, pharmacology, and suspected adverse drug reactions associated with nonsteroidal androgen antagonists in the United Kingdom

30 de April de 2026
Br J Clin Pharmacol. 2026 Apr 29. doi: 10.1002/bcp.70569. Online…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 2026-04-30 10:00:002026-04-30 10:00:00The interplay between molecular architecture, pharmacology, and suspected adverse drug reactions associated with nonsteroidal androgen antagonists in the United Kingdom

Charting the evolving landscape of kinase hinge-binding chemotypes beyond flatland: a systematic analysis and opportunities for sp3-rich binders

31 de January de 2026
Eur J Med Chem. 2026 Jan 19;306:118595. doi: 10.1016/j.ejmech.2026.118595.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 2026-01-31 11:00:002026-01-31 11:00:00Charting the evolving landscape of kinase hinge-binding chemotypes beyond flatland: a systematic analysis and opportunities for sp3-rich binders

Promiscuously bioactive compounds are prevalent in widely used commercial drug repurposing libraries

6 de January de 2026
Eur J Med Chem. 2025 Dec 31;305:118550. doi: 10.1016/j.ejmech.2025.118550.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 2026-01-06 11:00:002026-01-06 11:00:00Promiscuously bioactive compounds are prevalent in widely used commercial drug repurposing libraries

Concurrence of FGFR1 mutations modulates oncogenesis in glioneuronal tumors

1 de November de 2025
EMBO J. 2025 Oct 31. doi: 10.1038/s44318-025-00600-3. Online…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 2025-11-01 10:00:002025-11-01 10:00:00Concurrence of FGFR1 mutations modulates oncogenesis in glioneuronal tumors

The Chemical Probes Portal – 2024: update on this public resource to support best-practice selection and use of small molecules in biomedical research

18 de November de 2024
Nucleic Acids Res. 2024 Nov 18:gkae1062. doi: 10.1093/nar/gkae1062.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 2024-11-18 11:00:002024-11-18 11:00:00The Chemical Probes Portal – 2024: update on this public resource to support best-practice selection and use of small molecules in biomedical research

What is chemical biology?

20 de September de 2024
Cell Chem Biol. 2024 Sep 19;31(9):1562-1565. doi: 10.1016/j.chembiol.2024.08.011.ABSTRACTSince…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 2024-09-20 10:00:002024-09-20 10:00:00What is chemical biology?

Combining Data-Driven and Structure-Based Approaches in Designing Dual PARP1-BRD4 Inhibitors for Breast Cancer Treatment

18 de September de 2024
J Chem Inf Model. 2024 Sep 18. doi: 10.1021/acs.jcim.4c01421.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 2024-09-18 10:00:002024-09-18 10:00:00Combining Data-Driven and Structure-Based Approaches in Designing Dual PARP1-BRD4 Inhibitors for Breast Cancer Treatment

Polypharmacology prediction: the long road toward comprehensively anticipating small-molecule selectivity to de-risk drug discovery

15 de July de 2024
Expert Opin Drug Discov. 2024 Jul 14:1-27. doi: 10.1080/17460441.2024.2376643.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 2024-07-15 10:00:002024-07-15 10:00:00Polypharmacology prediction: the long road toward comprehensively anticipating small-molecule selectivity to de-risk drug discovery

Computational repurposing of oncology drugs through off-target drug binding interactions from pharmacological databases

17 de April de 2024
Clin Transl Med. 2024 Apr;14(4):e1657. doi: 10.1002/ctm2.1657.ABSTRACTPURPOSE:…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 2024-04-17 10:00:002024-04-17 10:00:00Computational repurposing of oncology drugs through off-target drug binding interactions from pharmacological databases

Identification of differential biological activity and synergy between the PARP inhibitor rucaparib and its major metabolite

9 de February de 2024
Cell Chem Biol. 2024 Feb 6:S2451-9456(24)00043-6. doi: 10.1016/j.chembiol.2024.01.007.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 2024-02-09 11:00:002024-02-09 11:00:00Identification of differential biological activity and synergy between the PARP inhibitor rucaparib and its major metabolite

Short-term exposure to environmental levels of nicotine and cotinine impairs visual motor response in zebrafish larvae through a similar mode of action: Exploring the potential role of zebrafish α7 nAChR

16 de December de 2023
Sci Total Environ. 2023 Dec 14:169301. doi: 10.1016/j.scitotenv.2023.169301.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 2023-12-16 11:00:002023-12-16 11:00:00Short-term exposure to environmental levels of nicotine and cotinine impairs visual motor response in zebrafish larvae through a similar mode of action: Exploring the potential role of zebrafish α7 nAChR

Elucidating Compound Mechanism of Action and Polypharmacology with a Large-scale Perturbational Profile Compendium

24 de October de 2023
bioRxiv. 2023 Oct 10:2023.10.08.561457. doi: 10.1101/2023.10.08.561457.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2023-10-24 10:00:002023-10-24 10:00:00Elucidating Compound Mechanism of Action and Polypharmacology with a Large-scale Perturbational Profile Compendium
Page 1 of 3123

Filter by categories

  • Alemany’s & Piulats’s lab (131)
  • Antolin's lab (36)
  • Aytes's Lab (24)
  • Belver's Lab (25)
  • Casanovas's Lab (77)
  • Martínez-Balibrea's Lab (43)
  • Menendez's Lab (121)
  • Molleví's Lab (35)
  • Pujana's Lab (110)
  • Sureda's & Farre's Lab (259)
  • Viñals's lab (111)

Twitter

Tweets by ProcureICO
Program Against Cancer Therapeutic Resistance

CONTACT US

Campus IDIBELL
(L’Hospitalet del Llobregat)
Hospital Duran i Reynals, Gran Via 199,
L’Hospitalet del Llobregat,
Barcelona 08908
Tel. +34 93 260 7952

Campus IGTP-IJC
(Badalona)
Campus Can Ruti – IGTP – Building Muntanya,
Rd. Can Ruti, Camí de les escoles s/n,
Badalona, Barcelona 08916
Tel. +34 93 554 3069

Campus IDIBGI
(Girona)
Parc Hospitalari Martí i Julià de Salt, Dr. Castany s/n,
Salt, Girona 17190
Tel. +34 872 987 087

© Copyright - Edisenius
  • Privacy Policy
  • Cookie Policy
  • Legal Notice
Scroll to top
Manage cookie consent
To offer the best experiences, we use technologies such as cookies to store and/or access device information. Consent to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Failure to consent, or withdrawal of consent, may adversely affect certain features and functions.
Functional Always active
Storage or technical access is strictly necessary for the legitimate purpose of allowing the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. Storage or technical access that is used exclusively for anonymous statistical purposes. Without a requirement, voluntary compliance by your Internet service provider, or additional records from a third party, information stored or retrieved solely for this purpose cannot be used to identify you.
Marketing
Storage or technical access is necessary to create user profiles to send advertising, or to track the user on a website or several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
See preferences
{title} {title} {title}